|Title||Associations of a metabolic syndrome severity score with coronary heart disease and diabetes in fasting vs. non-fasting individuals.|
|Publication Type||Journal Article|
|Year of Publication||2020|
|Authors||DeBoer MD, Filipp SL|
|Secondary Authors||Gurka MJ|
|Journal||Nutr Metab Cardiovasc Dis|
|Date Published||2020 01 03|
|Keywords||Biomarkers, Blood Glucose, Blood Pressure, Coronary Disease, Diabetes Mellitus, Type 2, Fasting, Female, Humans, Incidence, Lipids, Male, Metabolic Syndrome, Middle Aged, Predictive Value of Tests, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, United States|
BACKGROUND AND AIMS: Many traditional assessments of risk for coronary heart disease (CHD) and diabetes require laboratory studies performed after an 8-h fast. We assessed whether metabolic-syndrome (MetS) severity would remain linked to future CHD and diabetes even when assessed from non-fasting samples.
METHODS AND RESULTS: Participants in the Atherosclerosis Risk in Communities study were assessed at 4 visits and followed for 20-years of adjudicated CHD outcomes. We used Cox proportional-hazard models (for 20-year CHD outcomes) and logistic regression (for 9-year diabetes outcomes) to compare incident disease risk associated with a race/ethnicity-specific MetS-severity Z-score (MetS-Z) calculated in participants who were fasting (≥8 h) or non-fasting. All analyses were adjusted for sex, race, education, income and smoking. MetS Z-scores were overall similar between participants who were always fasting vs. those non-fasting at Visits 1-3 (all values -0.1 to 0.4), while MetS-Z for participants who were non-fasting at Visit-4 were higher at each visit. Baseline MetS-Z was linked to future CHD when calculated from both fasting and non-fasting measurements, with hazard ratio (HR) for fasting MetS-Z 1.53 (95% confidence interval [CI] 1.42, 1.66) and for non-fasting 1.28 (CI 1.08, 1.51). MetS-Z at Visit-1 also remained linked to future diabetes when measured from non-fasting samples, with odds ratio for fasting MetS-Z 3.10 (CI 2.88, 3.35) and for non-fasting 1.92 (CI 1.05, 3.51).
CONCLUSIONS: MetS-Z remained linked to future CHD and diabetes when assessed from non-fasting samples. A score such as this may allow for identification of at-risk individuals and serve as a motivation toward interventions to reduce risk.
|Alternate Journal||Nutr Metab Cardiovasc Dis|
|PubMed Central ID||PMC7393664|
|Grant List||R01 HL120960 / HL / NHLBI NIH HHS / United States|